Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Canadian (TSX) Pharma Industry Analysis

UpdatedJul 03, 2026
DataAggregated Company Financials
Companies54
  • 7D4.2%
  • 3M12.2%
  • 1Y54.5%
  • YTD1.9%

In the last week, the Pharma industry is up 4.2%, with Apotex Health up 4.5%. During this same period, the Noveris Health Sciences underperformed, falling 21%. This means that the industry has gained 54% over the past year. Looking forward, earnings are forecast to grow by 13% annually.

Industry Valuation and Performance

Has the Canadian Pharma Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Sat, 04 Jul 2026CA$14.4bCA$10.7b-CA$1,738,526,373.729.9x-8.3x1.3x
Mon, 01 Jun 2026CA$16.9bCA$12.1b-CA$1,891,923,461.118.2x-8.9x1.4x
Wed, 29 Apr 2026CA$17.3bCA$11.2b-CA$1,666,869,246.5215.3x-10.4x1.5x
Fri, 27 Mar 2026CA$13.7bCA$11.4b-CA$1,715,612,273.2811.8x-8x1.2x
Sun, 22 Feb 2026CA$14.2bCA$11.2b-CA$1,902,820,914.1914.6x-7.5x1.3x
Tue, 20 Jan 2026CA$16.5bCA$11.3b-CA$1,956,205,258.7316.1x-8.5x1.5x
Thu, 18 Dec 2025CA$20.6bCA$11.3b-CA$1,946,220,786.9415.6x-10.6x1.8x
Sat, 15 Nov 2025CA$14.6bCA$11.4b-CA$1,945,599,646.9414.9x-7.5x1.3x
Mon, 13 Oct 2025CA$17.2bCA$11.3b-CA$2,040,987,138.2035.1x-8.4x1.5x
Wed, 10 Sep 2025CA$17.0bCA$11.2b-CA$2,035,900,083.7238.1x-8.4x1.5x
Fri, 08 Aug 2025CA$12.5bCA$11.8b-CA$2,564,822,923.4718.2x-4.9x1.1x
Sun, 06 Jul 2025CA$10.1bCA$11.7b-CA$2,527,776,876.4717.2x-4x0.9x
Tue, 03 Jun 2025CA$9.8bCA$11.7b-CA$2,517,617,470.0519.4x-3.9x0.8x
Thu, 01 May 2025CA$10.5bCA$11.9b-CA$2,501,480,895.9320.9x-4.2x0.9x
Sat, 29 Mar 2025CA$10.5bCA$12.3b-CA$2,594,338,733.3519.5x-4x0.9x
Mon, 24 Feb 2025CA$12.0bCA$12.1b-CA$2,216,892,701.0621.8x-5.4x1x
Wed, 22 Jan 2025CA$12.6bCA$12.1b-CA$2,409,230,307.5728.9x-5.2x1x
Fri, 20 Dec 2024CA$12.6bCA$12.1b-CA$2,600,855,126.3719.4x-4.8x1x
Sun, 17 Nov 2024CA$14.9bCA$12.0b-CA$2,653,132,502.2016.2x-5.6x1.2x
Tue, 15 Oct 2024CA$18.4bCA$11.8b-CA$2,699,739,851.4518.1x-6.8x1.6x
Thu, 12 Sep 2024CA$18.0bCA$11.6b-CA$2,700,699,947.5520.5x-6.7x1.6x
Sat, 10 Aug 2024CA$19.3bCA$11.7b-CA$2,648,771,519.6723.6x-7.3x1.6x
Mon, 08 Jul 2024CA$19.0bCA$11.7b-CA$3,191,241,919.1818.5x-6x1.6x
Wed, 05 Jun 2024CA$20.9bCA$11.7b-CA$2,744,782,781.5213x-7.6x1.8x
Fri, 03 May 2024CA$25.2bCA$11.8b-CA$3,422,844,135.8311.7x-7.4x2.1x
Sun, 31 Mar 2024CA$25.0bCA$11.9b-CA$3,482,675,772.549.3x-7.2x2.1x
Tue, 27 Feb 2024CA$22.5bCA$12.0b-CA$4,647,759,588.679.5x-4.8x1.9x
Thu, 25 Jan 2024CA$21.0bCA$12.4b-CA$6,769,620,806.009.6x-3.1x1.7x
Sat, 23 Dec 2023CA$17.0bCA$12.2b-CA$6,715,146,418.008.6x-2.5x1.4x
Mon, 20 Nov 2023CA$18.0bCA$12.5b-CA$6,837,871,349.007.1x-2.6x1.4x
Wed, 18 Oct 2023CA$18.7bCA$12.4b-CA$7,330,037,148.0013.3x-2.5x1.5x
Fri, 15 Sep 2023CA$21.7bCA$12.9b-CA$7,891,240,783.0015.1x-2.7x1.7x
Sun, 13 Aug 2023CA$14.2bCA$13.1b-CA$8,044,261,319.0011.9x-1.8x1.1x
Tue, 11 Jul 2023CA$16.4bCA$13.2b-CA$9,521,691,924.0012.8x-1.7x1.2x
Price to Earnings Ratio

-1.7x


Total Market Cap: CA$16.4bTotal Earnings: -CA$9,521,691,924.00Total Revenue: CA$13.2bTotal Market Cap vs Earnings and Revenue0%0%0%
Canadian Pharma Industry Price to Earnings3Y Average -5.7x202420252026
Current Industry PE
  • Investors are relatively neutral on the Canadian Pharmaceuticals industry at the moment, indicating that they anticipate long term growth rates to remain steady.
  • The industry is trading close to its 3-year average PS ratio of 1.4x.
Past Earnings Growth
  • The earnings for companies in the Pharmaceuticals industry have improved over the last three years.
  • Meanwhile revenues for these companies have declined 6.8% per year.
  • This means that less sales are being generated overall, but since the cost of doing business is lower, losses have been shrinking.

Industry Trends

Which industries have driven the changes within the Canadian Healthcare industry?

CA Market0.26%
Healthcare3.26%
Pharma4.16%
Pharma4.16%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
CURA Curaleaf HoldingsCA$14.653.5%
+CA$129.4m		317.4%PS2.1x
APTX Apotex HealthCA$33.951.0%
+CA$77.7m		n/aPE20.8x
VRNO Verano HoldingsCA$9.0811.1%
+CA$66.3m		175.2%PS0.6x
GUD Knight TherapeuticsCA$9.914.9%
+CA$45.2m		63.8%PE173.4x
WEED Canopy GrowthCA$1.427.6%
+CA$42.2m		-19.3%PS2.1x

Latest News

WEED
CA$1.42
Canopy Growth
7D
7.6%
1Y
-19.3%
Narrative Update • Jul 02

WEED: German Medical Expansion And New Therapies Will Drive Future Upside

Analysts have trimmed their fair value estimate for Canopy Growth, reducing the implied price target from about CA$2.33 to roughly CA$2.02 as they incorporate slightly lower projected revenue growth and a more conservative future P/E assumption. What’s in the News for Canopy Growth Canopy Growth relaunched its Tweed brand in the German medical cannabis market, introducing three MTL Cannabis strains (Pablo’s Revenge, Dante’z Inferno, and Frost’d Flakes) as part of a broader plan to expand its product portfolio in Germany through 2026.
TSND
CA$0.91
TerrAscend
7D
-3.2%
1Y
142.7%
Narrative Update • Jul 02

TSND: Uplisting Preparations And New Jersey Dispensary Deal Will Support Upside

Analysts have lifted their CA$ price target on TerrAscend, reflecting a revised fair value estimate of CA$1.50. This figure is supported by updated assumptions for revenue growth, profit margins, and future P/E levels.
GSD
CA$7.50
Devonian Health Group
7D
-18.9%
1Y
-3.8%
APTX
CA$33.95
Apotex Health
7D
1.0%
1Y
n/a
VEXT
CA$0.23
Vext Science
7D
-6.3%
1Y
25.0%
NVRS
CA$1.44
Noveris Health Sciences
7D
-23.0%
1Y
476.0%
GRIN
CA$0.66
Grown Rogue International
7D
15.8%
1Y
32.0%
GTII
CA$10.86
Green Thumb Industries
7D
1.1%
1Y
48.2%
VRNO
CA$9.08
Verano Holdings
7D
11.1%
1Y
175.2%
Narrative Update • Jun 29

VRNO: Share Repurchase Plan Will Drive Future Upside Potential

Analysts have increased their fair value estimate for Verano Holdings from CA$4.21 to CA$24.73. They cite updated assumptions for discount rates, revenue growth, profit margins and a lower future P/E multiple as key drivers of the new price target range.
CURA
CA$14.65
Curaleaf Holdings
7D
3.5%
1Y
317.4%
BNXT
CA$0.33
BioNxt Solutions
7D
-8.3%
1Y
-44.1%
MDP
CA$5.14
Medexus Pharmaceuticals
7D
22.4%
1Y
65.3%
GUD
CA$9.91
Knight Therapeutics
7D
4.9%
1Y
63.8%
Narrative Update • Jun 25

GUD: Latin American Drug Launches And Renewed Coverage Will Drive Future Repricing

Analysts have lifted their price target on Knight Therapeutics by CA$1, reflecting updated assumptions for slightly higher revenue growth and profit margins, along with a modestly lower future P/E multiple. Analyst Commentary Recent research coverage on Knight Therapeutics points to a more constructive tone, with bullish analysts emphasizing the refreshed price target and renewed attention on the stock.
QNTM
CA$4.75
Quantum BioPharma
7D
-11.4%
1Y
-79.3%
XLY
CA$0.17
Auxly Cannabis Group
7D
-5.4%
1Y
34.6%
VREO
CA$13.98
Vireo Growth
7D
-1.0%
1Y
-22.3%